Liquid biopsy has been recognized as a promising tool in the fight against cancer. The active monitoring of cancer-associated biomarkers found in blood such as circulating tumor cells (CTC), may greatly advance the understanding of the disease and, thereby, improve the clinical outcome of cancer patients. SmartCatch is developing state-of-the-art technologies to make liquid biopsy accessible and an essential medical procedure for the diagnosis, follow-up and personalization of care in medical oncology. Extracting these tumor biomarkers from whole blood is challenging given their rareness and the complexity and rheological properties of the fluid. SmartCatch associates advanced computational fluid dynamics and cutting-edge microfabrication know-how in the development of its innovative solutions to lift these bottlenecks and enable a one-step physical and selective isolation of these tumor biomarkers from high volumes of blood in physiological conditions. SmartCatch’s innovation opens the doors of pan-omics and the future of precision medicine.